For patients with newly diagnosed multiple myeloma (NDMM) receiving dexamethasone induction, dose reductions do not ...

Medically reviewed by Marla Anderson, MD Multiple myeloma is a rare blood cancer that develops in the plasma cells, which are ...

Peripheral blood absolute lymphocyte count at diagnosis is an effective biomarker that can be used to risk-stratify patients with multiple myeloma, according to retrospective study results.Continued ...

Bryon Daily did not fit the profile of someone at risk for a rare blood condition. After all, he said he was under 60, physically fit, and had no family history of the disease. But after a seemingly ...

Recovery from multiple myeloma leads to a renewed sense of purpose and determination, with hope found in small victories. The ...

2024 was a year of resilience after a myeloma diagnosis, marked by a return to public speaking, a documentary filming experience and a fundraising walk.

They report a concerning relationship between micro and nanoplastic (MNP) concentrations in damaged tissues and links with multiple health conditions. Plastic usage soared from 1.5 million metric ...

CAR T-cell therapy modifies T cells to target cancer, showing promise in multiple myeloma treatment High costs and limited access make advanced cancer therapies unaffordable for many in India ...

It typically presents unilaterally and carries a favorable prognosis following surgical treatment. Ultrasound commonly reveals multiple slightly hyperechoic or isoechoic solid nodules with ipsilateral ...

Multiple myeloma and AL amyloidosis are conditions linked to plasma cells in the bone marrow. Multiple myeloma (MM) is a cancer affecting the plasma cells, which are mostly in the bone marrow.

The intricate interplay between malignant plasma cells and the bone marrow microenvironment has emerged as a focal point in multiple myeloma research, according to authors at the ASH Annual Meeting.